Form 8-K - Current report:
SEC Accession No. 0001628280-20-000118
Filing Date
2020-01-03
Accepted
2020-01-03 17:16:34
Documents
2
Period of Report
2020-01-03
Items
Item 2.01: Completion of Acquisition or Disposition of Assets
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K CLINIGEN PRODUCTS a8k-proformaclinigenproduc.htm 8-K 45446
2 EXHIBIT 99.1 clinigenproductsex991.htm EX-99.1 312052
  Complete submission text file 0001628280-20-000118.txt   358618
Mailing Address 2525 WEST END AVENUE SUITE 950 NASHVILLE TN 37203
Business Address 2525 WEST END AVENUE SUITE 950 NASHVILLE, TN 37203 615-255-0068
CUMBERLAND PHARMACEUTICALS INC (Filer) CIK: 0001087294 (see all company filings)

EIN.: 000000000 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-33637 | Film No.: 20506732
SIC: 2834 Pharmaceutical Preparations